Transcept to resubmit rejected sleep drug to FDA this month

Transcept Pharmaceuticals Inc. will resubmit its middle-of-the-night sleep drug for FDA approval this month, the company said Wednesday.
Following a meeting with the Food and Drug Administration, Richmond-based Transcept (NASDAQ: TSPT) said it will not undertake new studies of Intermezzo, its drug to help people who wake up in the middle of the night. The FDA rejected the drug in July, citing concerns that the lozenge would be used properly.